Home › Funds › Avidity Partners Management LP › BBOT

Avidity Partners Management LP position in BBOT

BridgeBio Oncology Therapeutic Inc · Health Care

Avidity Partners Management LP reported holding 43,853 shares of BBOT (BridgeBio Oncology Therapeutic Inc) in its Q2 2026 13F filing — a position valued at US$334K, representing 0.05% of its reported portfolio and ranking #43 among its reported holdings. Avidity Partners Management LP has disclosed BBOT holdings in 2 of the last 2 reported quarters, going back to Q1 2026.

Latest position (Q2 2026)43.85K sh
Reported value held$334.16K
Portfolio Weight0.05%
First reportedQ1 2026
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Avidity Partners Management LP's BBOT position evolved

Avidity Partners Management LP first disclosed a stake in BBOT in Q1 2026 at 43,853 shares (US$392K). Across 2 filings, Avidity Partners Management LP held the position steady without any share-count change. The most recent filing (Q2 2026) shows 43,853 shares valued at US$334K.

Quarter by quarter

QuarterSharesValueChange
Q1 2026 43.85K $392.48K New
Q2 2026 43.85K $334.16K Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BBOT and 13F data

BBOT (BridgeBio Oncology Therapeutic Inc) is a Health Care company. 74 other funds we track also report a position in BBOT — the largest reported positions include Cormorant Asset Management, LP (US$136.2M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$37.2M), Omega Fund Management, LLC (US$25.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BBOT

All BBOT fund holders →

FAQ

How long has Avidity Partners Management LP held BBOT?

Avidity Partners Management LP has disclosed BBOT holdings in 2 of the last 2 reported quarters, going back to Q1 2026.

What is Avidity Partners Management LP's current position in BBOT?

As of Q2 2026, Avidity Partners Management LP holds 43.85K shares of BBOT (BridgeBio Oncology Therapeutic Inc), valued at $334.16K, representing 0.05% of its reported portfolio and ranking #43.

Has Avidity Partners Management LP been buying or selling BBOT?

In the latest 13F filing (Q2 2026), Avidity Partners Management LP held unchanged its position in BBOT.

Which other funds hold BBOT?

Other major institutional holders of BBOT include Cormorant Asset Management, LP, DEERFIELD MANAGEMENT COMPANY, L.P., Omega Fund Management, LLC, among 74 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.